Eli Lilly’s rheumatoid arthritis medication Olumiant (baricitinib) may be the next treatment for COVID-19, thanks to AI analysis

Eli Lilly’s rheumatoid arthritis medication, Olumiant (baricitinib), is currently in phase 3 clinical trials to become a potential drug used in the treatment of COVID-19. This discovery was made possible by artificial intelligence analysis by BenevolentAI. BenevolentAI used machine learning to read through scientific literature to search for an approved drug that has the capability […]

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

A breakthrough has been discovered in one of the world’s biggest randomized, controlled trials for coronavirus treatment. Based in the United Kingdom, the RECOVERY trial enrolled a total of 2,100 participants who received an inexpensive and commonly used steroid, dexamethasone. The participants were compared to 4,300 people who received standard care. The cohorts showing the […]

FDA Approves First Drug for Imaging Tau Pathology in Alzheimer’s Disease

Tauvid (flortaucipir F18) was recently approved for intravenous injection during PET imaging of for patients being evaluated for Alzheimer’s disease after being granted Priority Review by the FDA. Tauvid is a radioactive diagnostic agent indicated for use during PET imaging to estimate the density and distribution of tau-associated neurofibrillary tangles (NFTs), which is a primary […]

The Effect of Personality Traits on Risk of Incident Pre‐dementia Syndromes

An intriguing new study was published this month in The Journal of the American Geriatrics Society, proposing that personality traits may be a valuable predictor for the risk of developing pre-dementia syndromes.    The impact of personality traits have been observed previously by researchers who linked traits such as neuroticism and conscientiousness to dementia and […]

This Just In: FDA Approves Antibiotic to Treat Hospital-Acquired (HAP) and Ventilator-Acquired (VAP) Bacterial Pneumonia

On June 4th, 2020 the FDA approved Recarbrio (imipenem-cilastatin and relebactam) to treat HAP/VAP in patients over 18 years old. This drug includes imipenem, which binds to PBP 2 and  PBP 1B on certain bacteria therefore inhibiting PBP leading to the disruption of bacterial cell wall synthesis, and cilastatin which is a renal dehydropeptidase inhibitor […]

FDA Authorizes First Standalone At-Home Sample Collection Kit for COVID-19 Diagnostic Testing

The FDA has officially authorized the first at-home sample collection kit that can be sent off to two different laboratories for COVID-19 diagnostic testing. Everlywell, Inc. was issued an emergency use authorization (EUA) from the FDA for its at-home COVID-19 sample collection kit. The kit is authorized to be used by individuals in the comfort […]

Web Design by Venbit
Privacy Policy